Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Interest & Investment Income: 2016-2024

Historic Interest & Investment Income for Cidara Therapeutics (CDTX) over the last 9 years, with Dec 2024 value amounting to $5.8 million.

  • Cidara Therapeutics' Interest & Investment Income rose 190.21% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 138.08%. This contributed to the annual value of $5.8 million for FY2024, which is 191.28% up from last year.
  • According to the latest figures from FY2024, Cidara Therapeutics' Interest & Investment Income is $5.8 million, which was up 191.28% from $2.0 million recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Interest & Investment Income peaked at $5.8 million during FY2024, and registered a low of -$262,000 during FY2020.
  • Over the past 3 years, Cidara Therapeutics' median Interest & Investment Income value was $2.0 million (recorded in 2023), while the average stood at $2.7 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Interest & Investment Income slumped by 218.55% in 2020, and later spiked by 944.50% in 2023.
  • Over the past 5 years, Cidara Therapeutics' Interest & Investment Income (Yearly) stood at -$262,000 in 2020, then rose by 19.08% to -$212,000 in 2021, then soared by 190.09% to $191,000 in 2022, then skyrocketed by 944.50% to $2.0 million in 2023, then surged by 191.28% to $5.8 million in 2024.